Abstract
Co-administration of probiotics and antibiotics has been used to prevent or treat primary Clostridioides difficile (pCDI), and the closer the interval between the combination, the more effective it is, but the reason behind this is unknown. In this study, the cell-free culture supernatant (CFCS) of Bifidobacterium breve YH68 was used in combination with vancomycin (VAN) and metronidazole (MTR) to treat C. difficile cells. The growth and biofilm production of C. difficile under different co-administration time interval treatments were determined by optical density and crystalline violet staining, respectively. The toxin production of C. difficile was determined by enzyme immunoassay, and the relative expressions of C. difficile virulence genes tcdA and tcdB were determined by real-time qPCR method. Meanwhile, the types and contents of organic acids in YH68-CFCS were investigated by LC-MS/MS. The results showed that YH68-CFCS in combination with VAN or MTR significantly inhibited the growth, biofilm production, and toxin production of C. difficile in the effective time interval range (0–12 h) but did not affect the expression level of C. difficile virulence genes. In addition, the effective antibacterial component of YH68-CFCS is lactic acid (LA).
This is a preview of subscription content, log in via an institution to check access.
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
Data availability
The authors confirm that the data supporting the findings of this study are available within the article.
References
Aguirre AM, Sorg JA (2022) Gut associated metabolites and their roles in Clostridioides difficile pathogenesis. Gut Microbes 14(1):2094672. https://doi.org/10.1080/19490976.2022.2094672
De Filippis F, Esposito A, Ercolini D (2022) Outlook on next-generation probiotics from the human gut. Cell Mol Life Sci. 79:76. https://doi.org/10.1007/s00018-021-04080-6
Feuerstadt P, Louie TJ, Lashner B, Wang EEL, Diao L, Bryant JA, Sims M, Kraft CS, Cohen SH, Berenson CS, Korman LY, Ford CB, Litcofsky KD, Lombardo M-J, Wortman JR, Wu H, Aunins JG, McChalicher CWJ, Winkler JA, McGovern BH, Trucksis M, Henn MR, von Moltke L (2022) SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. New Engl J Med 386(3):220–229. https://doi.org/10.1056/NEJMoa2106516
Fiori J, Amadesi E, Fanelli F, Tropeano CV, Rugolo M (2018) Gotti R (2017) Cellular and mitochondrial determination of low molecular mass organic acids by LC-MS/MS. J Pharm Biomed Anal 150:33–38. https://doi.org/10.1007/10.1016/j.jpba.2017.11.071
Fukuda S, Toh H, Hase K, Oshima K, Nakanishi Y, Yoshimura K et al (2011) Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 469:543–7. https://doi.org/10.1038/nature09646
Karetkin BA, Guseva EV, Evdokimova SA, Mishchenko AS, Khabibulina NV, Grosheva VD et al (2019) A quantitative model of Bacillus cereus ATCC 9634 growth inhibition by bifidobacteria for synbiotic effect evaluation. World J Microbiol Biotechnol 35:89. https://doi.org/10.1007/s11274-019-2665-2
Mimee M, Citorik RJ, Lu TK (2016) Microbiome therapeutics - advances and challenges. Adv Drug Deliv Rev 105(Pt A):44–54. https://doi.org/10.1016/j.addr.2016.04.032
Mosca A, Abreu YAAT, Gwee KA, Ianiro G, Tack J, Nguyen TVH et al (2022) The clinical evidence for postbiotics as microbial therapeutics. Gut Microbes 14:2117508. https://doi.org/10.1080/19490976.2022.2117508
Nguyen BT, Bujna E, Fekete N, Tran ATM, Rezessy-Szabo JM, Prasad R et al (2019) Probiotic beverage from pineapple juice fermented with Lactobacillus and Bifidobacterium strains. Front Nutr 6:54. https://doi.org/10.3389/fnut.2019.00054
Pawlak M, Klupczynska A, Kokot ZJ (2019) Matysiak J (2019) Extending metabolomic studies of Apis mellifera venom: LC-MS-based targeted analysis of organic acids. Toxins 12(1):14. https://doi.org/10.3390/toxins12010014
Peluzio MdCG, Martinez JA, Milagro FI (2021) Postbiotics: metabolites and mechanisms involved in microbiota-host interactions. Trends Food Sci Tech 108:11–26. https://doi.org/10.1016/j.tifs.2020.12.004
Quigley EMM (2019) Prebiotics and probiotics in digestive health. Clin Gastroenterol Hepatol 17(2):333–344. https://doi.org/10.1016/j.cgh.2018.09.028
Rui W, Gu C, Zhang H, Liao X, Zhao X, Xu Y, Yang J (2022) Antagonistic activity of selenium-enriched Bifidobacterium breve against Clostridioides difficile. Appl Microbiol Biotechnol 106(18):6181–6194. https://doi.org/10.1007/s00253-022-12124-5
Salminen S, Collado MC, Endo A, Hill C, Lebeer S, Quigley EMM, Sanders ME, Shamir R, Swann JR, Szajewska H, Vinderola G (2021) The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat Rev Gastroenterol Hepatol 18(9):649–667. https://doi.org/10.1038/s41575-021-00440-6
Sehgal K, Cifu AS, Khanna S (2022) Treatment of Clostridioides difficile infection. JAMA. https://doi.org/10.1001/jama.2022.12251
Shen NT, Maw A, Tmanova LL, Pino A, Ancy K, Crawford CV, Simon MS, Evans AT (2017) Timely use of probiotics in hospitalized adults prevents Clostridium difficile infection: a systematic review with meta-regression analysis. Gastroenterology 152(8):1889–19009. https://doi.org/10.1053/j.gastro.2017.02.003
Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ (2016) Clostridium difficile infection. Nat Rev Dis Primers 2:16020. https://doi.org/10.1038/nrdp.2016.20
Suez J, Zmora N, Segal E, Elinav E (2019) The pros, cons, and many unknowns of probiotics. Nat Med 25(5):716–729. https://doi.org/10.1038/s41591-019-0439-x
Yang J, Yang H (2018) Effect of Bifidobacterium breve in combination with different antibiotics on Clostridium difficile. Front Microbiol 9(2953). https://doi.org/10.3389/fmicb.2018.02953
Funding
This work was supported by the National Natural Science Foundation of China (No. 32200154).
Author information
Authors and Affiliations
Contributions
JPY conceptualized the presented idea, supervised the findings, analyzed the results, and wrote the manuscript. YNL and LTM performed the bioinformatics analysis of the data. JPY and LTM helped in the sampling and sample processing. JPY supervised the project and acquired financial support for the project leading to this publication. All authors read and approved the manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Yang, J., Li, Y. & Meng, L. Combination of Bifidobacterium breve and antibiotics against Clostridioides difficile: effect of the time interval of combination on antagonistic activity. Int Microbiol 26, 833–840 (2023). https://doi.org/10.1007/s10123-023-00340-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10123-023-00340-6